Aberdeen Group
SPTX icon

Aberdeen Group’s Seaport Therapeutics SPTX Stock Holding History

Aberdeen Group’s Portfolio SPTX Stock Details SPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$35.9M Sell
267,678
-42,677
-14% -$948K 0.05% 316
2026
Q2 		$6.74M Buy
+310,355
New +$5.46M 0.01% 657

Other funds holding SPTX

Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Aberdeen Group's SPTX Position: Q3 2026 in Review

Aberdeen Group reduced its Seaport Therapeutics (SPTX) stake by 14% in Q3 2026, selling an estimated $948K and leaving 267,678 shares worth $35.9M. The position accounts for 0.05% of the portfolio, ranked #316.

Aberdeen Group first reported a position in SPTX in Q2 2026 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold SPTX as of Q3 2026.

  • Aberdeen Group held 267,678 shares of Seaport Therapeutics worth $35.9M as of Q3 2026.
  • Aberdeen Group sold 42,677 Seaport Therapeutics shares in Q3 2026, an estimated $948K.
  • Seaport Therapeutics made up 0.05% of Aberdeen Group's portfolio in Q3 2026, its #316 holding.
  • Aberdeen Group first reported a position in Seaport Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 13 funds tracked by Wall St. Rank held Seaport Therapeutics as of Q3 2026.

Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.